AvaGen:
Early Prevention

Preemptive genetic testing opens up the advantages of early treatment for patients at risk for genetic eye disease. Onset may be delayed, symptoms may be mitigated, and outcomes may be redirected or changed.

Discovering genetic information early in a patient’s lifetime could make a meaningful difference in terms of the quality of life for patients and their families.

Tactics to help slow progression

Keratoconus, the most common primary corneal ectasia disorder, cannot be prevented at this present time. However, early intervention may slow or delay the onset or the progression of symptoms. The techniques below may help.

Preventive techniques for keratoconus:

  • Regular eye tests for all family members above 10 years of age, especially for families with a
    history of keratoconus or certain risk factors
  • Avoid rubbing eyes
  • Follow physician instructions and immediately report issues or suspected disease
    progression
  • Avoid unprescribed medications, even if recommended by a keratoconus patient
  • Keep eyes clean
  • Protect against eye irritations
  • Protect eyes while swimming and other sports

Identifying corneal dystrophies earlier

Many patients are unable to provide an accurate family history of corneal dystrophy, says Dr Julie Schallhorn, University of California, San Francisco.

"With the prevalence of keratoconus increasing and now that effective treatments are available, it is pertinent to diagnose as early as possible to make personalized management decisions to prevent vision loss."

Melissa Barnett, OD

New opportunities for earlier disease protection

The American Academy of Ophthalmology (AAO) believes pre-symptomatic testing offers 3 potential advantages2:

A physician can administer a preventive
therapy before clinically detectable
damage to tissues has occurred

A physician can increase
surveillance for treatable
manifestations of the disease

At-risk individuals can make informed
lifestyle decisions at a time in their
lives when a disease is not yet
clinically detectable

Assessing keratoconus is multifactorial

Until now genetic information has been missing.

"Study findings suggest that we are likely seeing many more patients with keratoconus as well as patients who are at increased risk for keratoconus."

William Trattler, MD

Prevalence of keratoconus

Keratoconus prevalence may be considerably higher than previously reported, particularly in certain patient groups. View this clinical paper for one perspective.

Prevalence of keratoconus in pediatric patients in Riyadh, Saudi Arabia

Torres-Netto EA, Al-Otabi WM, Hafezi NL

How genetic tests such as AvaGen may help

DNA-based testing methods such as AvaGen can uncover a patient’s predisposition to disease years or even decades earlier than the disease would otherwise be detectable by the most sensitive, existing clinical tools. DNA testing gives physicians and patients a unique opportunity to collaborate proactively toward improved outcomes.

Learn about the potential of AvaGen

Explore_Icon.png